Antibe Therapeutics Inc. ("Antibe" or the "Corporation") (TSXV:ATE; OTCQX:ATBPF) is pleased to announce the expansion of its Clinical Advisory Board with the appointment of Canadian rheumatologist J. Carter Thorne, MD, FRCP(C), FACP, Chief of the Division of Rheumatology and Director of The Arthritis Program at Southlake Regional Health Centre in Newmarket, Canada. Dr. Thorne holds a Fellowship with the Royal College of Physicians in Internal Medicine and Rheumatology FRCP(C), and is also a Fellow at the American College of Physicians and American College of Rheumatology FACP. Dr. Thorne sits on numerous national and international steering and scientific committees identifying and disseminating outcomes and best practices in the management of arthritis. Dr. Thorne is active in clinical research as Principal Investigator with The Arthritis Program (TAP) Research Group and was secretary-treasurer and a founding member of the Canadian Rheumatology Research Consortium. He sits on the Steering and Scientific Committee of the Ontario Best Practices Research Initiative, and is a founding member and past-president of the Ontario Rheumatology Association (ORA) and past-president of the Canadian Rheumatology Association (CRA). At the international level, Dr. Thorne is the past secretary-treasurer of the Pan-American League Against Rheumatism (PANLAR), and sits on the steering committee of the American College of Rheumatology's CARE (Continuing Assessment, Review, and Evaluation) Program. Antibe's Chief Science Officer, Dr. John Wallace, remarked: "We are excited and honoured to have Dr. Thorne, a well-respected physician and researcher join our Clinical Advisory Board. Through his involvement in multiple initiatives, Dr. Thorne has not only improved the treatment and care of patients with arthritis but also contributed significantly to the profession's enhanced knowledge of arthritis care both in Canada and around the globe." Non-steroidal anti-inflammatory drugs (NSAIDs) are used to treat inflammatory conditions such as arthritis, but are associated with serious and potentially life-threatening side effects, including gastrointestinal ulceration and bleeding. Antibe's lead drug, ATB-346, is a hydrogen sulfide-releasing derivative of naproxen, one of the most prescribed NSAIDs globally. In pre-clinical testing, ATB-346 exhibited comparable anti-inflammatory activity to naproxen, but with negligible adverse effects. ATB-346 is presently being evaluated in a phase I human clinical trial. The Clinical Advisory Board will play a major role in designing Antibe's future clinical development program, aimed at demonstrating the effectiveness and improved safety of ATB-346.
About Antibe Therapeutics Inc.Antibe develops safer medicines for pain and inflammation. Antibe's technology involves linking a hydrogen sulfide-releasing molecule to an existing drug to produce a patented, improved medicine. Antibe's lead drug ATB-346 targets the global need for a safer non-steroidal anti-inflammatory drug (NSAID) for chronic pain and inflammation. ATB-352, the second drug in Antibe's pipeline, targets the urgent global need for a safer analgesic for severe acute pain. www.antibethera.com Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Important Note on Forward Looking Statements